Tumors of the Pancreas

Sleisenger and Fordtran’s Gastrointestinal and Liver Disease- 2 Volume Set: Pathophysiology, Diagnosis, Management, Expert Consult Premium Edition - Enhanced Online Features and Print

Volumn , Issue , 2010, Pages 1017-1034

  Jimenez, Ramon E ^a,b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85124860785     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6189-2.00060-3     Document Type: Chapter

References (207)

1. Balcom JH., Rattner DW., Warshaw AL., et al. Ten-year experience with 733 pancreatic resections: Changing indications, older patients, and decreasing length of hospitalization Arch Surg 136 2001 391-398(Ref 103.)
2. Bilimoria KY., Bentrem DJ., Ko CY., et al. National failure to operate on early stage pancreatic cancer Ann Surg 246 2007 173-180(Ref 111.)
3. Birkmeyer JD., Finlayson SR., Tosteson AN., et al. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy Surgery 125 1999 250-256(Ref 109.)
4. Brugge WR., Lauwers GY., Sahani D., et al. Cystic neoplasms of the pancreas N Engl J Med 351 2004 1218-1226(Ref 154.)
5. Burris HA III., Moore MJ., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial J Clin Oncol 15 1997 2403-2413(Ref 141.)
6. Crippa S., Salvia R., Warshaw AL., et al. Mucinous cystic neoplasm of the pancreas is not an aggressive entity: Lessons from 163 resected patients Ann Surg 247 2008 571-579(Ref 163.)
7. Ductal adenocarcinoma In: Hruban RH., Pitman MB., Klimstra DS AFIP Atlas of Tumor Pathology. Tumors of the Pancreas 2007 American Registry of Pathology Washington, D.C. 111-164(Ref 22.)
8. Gress FG., Hawes RH., Savides TJ., et al. Role of EUS in the preoperative staging of pancreatic cancer: A large single-center experience Gastrointest Endosc 50 1999 786-791(Ref 63.)
9. Hezel AF., Kimmelman AC., Stanger BZ., et al. Genetics and biology of pancreatic ductal adenocarcinoma Genes Dev 20 2006 1218-1249(Ref 28.)
10. Jimenez RE., Warshaw AL., Rattner DW., et al. Impact of laparoscopic staging in the treatment of pancreatic cancer Arch Surg 135 2000 409-414(Ref 88.)
11. Lowenfels AB., Maisonneuve P., DiMagno EP., et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group J Natl Cancer Inst 89 1997 442-446(Ref 3.)
12. Neoptolemos JP., Stocken DD., Friess H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 2004 1200-1210(Ref 134.)
13. O’Malley ME., Boland GW., Wood BJ., et al. Adenocarcinoma of the head of the pancreas: Determination of surgical unresectability with thin-section pancreatic-phase helical CT AJR Am J Roentgenol 173 1999 1513-1518(Ref 52.)
14. Salvia R., Fernandez-del Castillo C., Bassi C., et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: Clinical predictors of malignancy and long-term survival following resection Ann Surg 239 2004 678-685(Ref 177.)
15. Yeo CJ., Cameron JL., Lillemoe KD., et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: Randomized controlled trial evaluating survival, morbidity, and mortality Ann Surg 236 2002 355-366(Ref 102.)
16. American Cancer Society Cancer Facts and Figures 2008 2008 American Cancer Society Atlanta.
17. Ries LAG., Eisner MP., Kosary CL SEER Cancer Statistics Review, 1973-1996 2000 National Cancer Institute Bethesda, Md.
18. Lowenfels AB., Maisonneuve P., DiMagno EP., et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group J Natl Cancer Inst 89 1997 442-446.
19. Lowenfels AB., Maisonneuve P., Cavallini G., et al. Pancreatitis and the risk of pancreatic cancer. International pancreatitis study group N Engl J Med 328 1993 1433-1437.
20. Giardiello FM., Brensinger JD., Tersmette AC., et al. Very high risk of cancer in familial Peutz-Jeghers syndrome Gastroenterology 119 2000 1447-1453.
21. Lynch HT., Fusaro RM., Lynch JF., et al. Pancreatic cancer and the FAMMM syndrome Fam Cancer 7 2008 103-112.
22. Couch FJ., Johnson MR., Rabe KG., et al. The prevalence of BRCA2 mutations in familial pancreatic cancer Cancer Epidemiol Biomarkers Prev 16 2007 342-346.
23. Hruban RH., Petersen GM., Goggins M., et al. Familial pancreatic cancer Ann Oncol 10 1999 69-73.
24. Klein AP., Brune KA., Petersen GM., et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds Cancer Res 64 2004 2634-2638.
25. DiMagno EP., Reber HA., Tempero MA AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association Gastroenterology 117 1999 1464-1484.
26. Klapman J., Malafa MP Early detection of pancreatic cancer: Why, who, and how to screen Cancer Control 15 2008 280-287.
27. Ahlgren JD Epidemiology and risk factors in pancreatic cancer Semin Oncol 23 1996 241-250.
28. Silverman DT., Dunn JA., Hoover RN., et al. Cigarette smoking and pancreas cancer: A case-control study based on direct interviews J Natl Cancer Inst 86 1994 1510-1516.
29. Fuchs CS., Colditz GA., Stampfer MJ., et al. A prospective study of cigarette smoking and the risk of pancreatic cancer Arch Intern Med 156 1996 2255-2260.
30. Ghadirian P., Simard A., Baillargeon J Tobacco, alcohol, and coffee and cancer of the pancreas. A population-based, case-control study in Quebec, Canada Cancer 67 1991 2664-2670.
31. Duell EJ., Holly EA., Bracci PM., et al. A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk J Natl Cancer Inst 94 2002 297-306.
32. Farrow DC., Davis S Diet and the risk of pancreatic cancer in men Am J Epidemiol 132 1990 423-431.
33. Howe GR., Jain M., Miller AB Dietary factors and risk of pancreatic cancer: Results of a Canadian population-based case-control study Int J Cancer 45 1990 604-608.
34. Burney PG., Comstock GW., Morris JS Serologic precursors of cancer: Serum micronutrients and the subsequent risk of pancreatic cancer Am J Clin Nutr 49 1989 895-900.
35. Gullo L., Pezzilli R., Morselli-Labate AM Diabetes and the risk of pancreatic cancer. Italian Pancreatic Cancer Study Group N Engl J Med 331 1994 81-84.
36. Permert J., Larsson J., Westermark GT., et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes N Engl J Med 330 1994 313-318.
37. Ductal adenocarcinoma In: Hruban RH., Pitman MB., Klimstra DS AFIP Atlas of Tumor Pathology. Tumors of the Pancreas 2007 American Registry of Pathology Washington, D.C. 111-164.
38. Kloppel G., Hruban RH., Longnecker DS., et al. Tumours of the exocrine pancreas In: Hamilton SR., Aaltonen LA World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System 2000 IARC Press Lyon, France 219-251.
39. Tumors of the exocrine pancreas In: Solcia E., Capella C., Kloppel G Tumors of the Pancreas 1997 Armed Forces Institute of Pathology Washington, D.C. 31-144.
40. Luttges J., Schemm S., Vogel I., et al. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation J Pathol 191 2000 154-161.
41. Hruban RH., Adsay NV., Bores-Saavedra J., et al. Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions Am J Surg Pathol 25 2001 579-586.
42. Wilentz RE., Iacobuzio-Donahue CA., Argani P., et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression Cancer Res 60 2000 2002-2006.
43. Hezel AF., Kimmelman AC., Stanger BZ., et al. Genetics and biology of pancreatic ductal adenocarcinoma Genes Dev 20 2006 1218-1249.
44. Jimenez RE., Warshaw AL., Z’Graggen K., et al. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy Ann Surg 230 1999 501-509.
45. Z’Graggen K., Rivera JA., Compton CC., et al. Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas Ann Surg 226 1997 491-498.
46. Rivera JA., Rall CJ., Graeme-Cook F., et al. Analysis of K-ras oncogene mutations in chronic pancreatitis with ductal hyperplasia Surgery 121 1997 42-49.
47. Moskaluk CA., Hruban RH., Kern SE p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma Cancer Res 57 1997 2140-2143.
48. Sherr CJ The INK4a/ARF network in tumour suppression Nat Rev Mol Cell Biol 2 2001 731-737.
49. Goldstein AM., Fraser MC., Struewing JP., et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations N Engl J Med 333 1995 970-974.
50. Rozenblum E., Schutte M., Goggins M., et al. Tumor-suppressive pathways in pancreatic carcinoma Cancer Res 57 1997 1731-1734.
51. Hahn SA., Schutte M., Hoque AT., et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1 Science 271 1996 350-353.
52. Chiao PJ., Hunt KK., Grau AM., et al. Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle Ann N Y Acad Sci 880 1999 31-37.
53. Friess H., Berberat P., Schilling M., et al. Pancreatic cancer: The potential clinical relevance of alterations in growth factors and their receptors J Mol Med 74 1996 35-42.
54. Van Heek NT., Meeker AK., Kern SE., et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia Am J Pathol 161 2002 1541-1547.
55. Thayer SP., di Magliano MP., Heiser PW., et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis Nature 425 2003 851-856.
56. Li D., Xie K., Wolff R., et al. Pancreatic cancer Lancet 363 2004 1049-1057.
57. Sohn TA., Lillemoe KD., Cameron JL., et al. Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s J Am Coll Surg 188 1999 658-666.
58. Fasanella KE., Davis B., Lyons J., et al. Pain in chronic pancreatitis and pancreatic cancer Gastroenterol Clin North Am 36 2007 335-364 ix.
59. Yalniz M., Pour PM Diabetes mellitus: A risk factor for pancreatic cancer? Langenbecks Arch Surg 390 2005 66-72.
60. Mujica VR., Barkin JS., Go VL Acute pancreatitis secondary to pancreatic carcinoma. Study group participants Pancreas 21 2000 329-332.
61. Coley SC., Strickland NH., Walker JD., et al. Spiral CT and the pre-operative assessment of pancreatic adenocarcinoma Clin Radiol 52 1997 24-30.
62. Freeny PC., Traverso LW., Ryan JA Diagnosis and staging of pancreatic adenocarcinoma with dynamic computed tomography Am J Surg 165 1993 600-606.
63. Megibow AJ., Zhou XH., Rotterdam H., et al. Pancreatic adenocarcinoma: CT versus MR imaging in the evaluation of resectability-Report of the Radiology Diagnostic Oncology Group Radiology 195 1995 327-332.
64. Boland GW., O’Malley ME., Saez M., et al. Pancreatic-phase versus portal vein-phase helical CT of the pancreas: Optimal temporal window for evaluation of pancreatic adenocarcinoma AJR Am J Roentgenol 172 1999 605-608.
65. Lu DS., Vedantham S., Krasny RM., et al. Two-phase helical CT for pancreatic tumors: Pancreatic versus hepatic phase enhancement of tumor, pancreas, and vascular structures Radiology 199 1996 697-701.
66. Lu DS., Reber HA., Krasny RM., et al. Local staging of pancreatic cancer: Criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT AJR Am J Roentgenol 168 1997 1439-1443.
67. O’Malley ME., Boland GW., Wood BJ., et al. Adenocarcinoma of the head of the pancreas: Determination of surgical unresectability with thin-section pancreatic-phase helical CT AJR Am J Roentgenol 173 1999 1513-1518.
68. Raptopoulos V., Steer ML., Sheiman RG., et al. The use of helical CT and CT angiography to predict vascular involvement from pancreatic cancer: Correlation with findings at surgery AJR Am J Roentgenol 168 1997 971-977.
69. Sahani DV., Shah ZK., Catalano OA., et al. Radiology of pancreatic adenocarcinoma: Current status of imaging J Gastroenterol Hepatol 23 2008 23-33.
70. Glasbrenner B., Ardan M., Boeck W., et al. Prospective evaluation of brush cytology of biliary strictures during endoscopic retrograde cholangiopancreatography Endoscopy 31 1999 712-717.
71. Levy MJ., Baron TH., Clayton AC., et al. Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures Am J Gastroenterol 103 2008 1263-1273.
72. Pisters PW., Hudec WA., Hess KR., et al. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients Ann Surg 234 2001 47-55.
73. Povoski SP., Karpeh MS Jr., Conlon KC., et al. Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy Ann Surg 230 1999 131-142.
74. Sohn TA., Yeo CJ., Cameron JL., et al. Do preoperative biliary stents increase postpancreaticoduodenectomy complications? J Gastrointest Surg 4 2000 258-267.
75. Prat F., Chapat O., Ducot B., et al. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct Gastrointest Endosc 47 1998 1-7.
76. Soriano A., Castells A., Ayuso C., et al. Preoperative staging and tumor resectability assessment of pancreatic cancer: Prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography Am J Gastroenterol 99 2004 492-501.
77. DeWitt J., Devereaux B., Chriswell M., et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer Ann Intern Med 141 2004 753-763.
78. Gress FG., Hawes RH., Savides TJ., et al. Role of EUS in the preoperative staging of pancreatic cancer: A large single-center experience Gastrointest Endosc 50 1999 786-791.
79. Gress F., Gottlieb K., Sherman S., et al. Endoscopic ultrasonography-guided fine-needle aspiration biopsy of suspected pancreatic cancer Ann Intern Med 134 2001 459-464.
80. Rosch T., Dittler HJ., Strobel K., et al. Endoscopic ultrasound criteria for vascular invasion in the staging of cancer of the head of the pancreas: A blind reevaluation of videotapes Gastrointest Endosc 52 2000 469-477.
81. Ichikawa T., Haradome H., Hachiya J., et al. Pancreatic ductal adenocarcinoma: Preoperative assessment with helical CT versus dynamic MR imaging Radiology 202 1997 655-662.
82. Lopez HE., Amthauer H., Hosten N., et al. Prospective evaluation of pancreatic tumors: Accuracy of MR imaging with MR cholangiopancreatography and MR angiography Radiology 224 2002 34-41.
83. Barish MA., Yucel EK., Ferrucci JT Magnetic resonance cholangiopancreatography N Engl J Med 341 1999 258-264.
84. Adamek HE., Albert J., Breer H., et al. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: A prospective controlled study Lancet 356 2000 190-193.
85. Inokuma T., Tamaki N., Torizuka T., et al. Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer J Nucl Med 36 1995 229-235.
86. Zimny M., Bares R., Fass J., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: A report of 106 cases Eur J Nucl Med 24 1997 678-682.
87. Rose DM., Delbeke D., Beauchamp RD., et al. 18-Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer Ann Surg 229 1999 729-737.
88. DelMaschio A., Vanzulli A., Sironi S., et al. Pancreatic cancer versus chronic pancreatitis: Diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy Radiology 178 1991 95-99.
89. Parsons L Jr., Palmer CH How accurate is fine-needle biopsy in malignant neoplasia of the pancreas? Arch Surg 124 1989 681-683.
90. Webb TH., Lillemoe KD., Pitt HA., et al. Pancreatic lymphoma. Is surgery mandatory for diagnosis or treatment? Ann Surg 209 1989 25-30.
91. Ritts RE., Pitt HA CA 19-9 in pancreatic cancer Surg Oncol Clin North Am 7 1998 93-101.
92. Safi F., Schlosser W., Falkenreck S., et al. CA 19-9 serum course and prognosis of pancreatic cancer Int J Pancreatol 20 1996 155-161.
93. Halm U., Schumann T., Schiefke I., et al. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer Br J Cancer 82 2000 1013-1016.
94. Hess V., Glimelius B., Grawe P., et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial Lancet Oncol 9 2008 132-138.
95. Exocrine pancreas In: Greene FL., Page DL., Fleming ID., et al. AJCC Cancer Staging Manual 2002 Springer-Verlag New York 157-162.
96. Sener SF., Fremgen A., Menck HR., et al. Pancreatic cancer: A report of treatment and survival trends for 100, 313 patients diagnosed from 1985-1995, using the National Cancer Database J Am Coll Surg 189 1999 1-7.
97. Czito BG., Willett CG., Clark JW., et al. Current perspectives on locally advanced pancreatic cancer Oncology (Huntingt) 14 2000 1535-1545.
98. Moertel CG., Frytak S., Hahn RG., et al. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group Cancer 48 1981 1705-1710.
99. Willett CG., Del Castillo CF., Shih HA., et al. Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer Ann Surg 241 2005 295-299.
100. Katz MH., Pisters PW., Evans DB., et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease J Am Coll Surg 206 2008 833-846.
101. Bemelman WA., de Wit LT., van Delden OM., et al. Diagnostic laparoscopy combined with laparoscopic ultrasonography in staging of cancer of the pancreatic head region Br J Surg 82 1995 820-824.
102. Fernandez-del Castillo C., Rattner DW., Warshaw AL Further experience with laparoscopy and peritoneal cytology in the staging of pancreatic cancer Br J Surg 82 1995 1127-1129.
103. Jimenez RE., Warshaw AL., Rattner DW., et al. Impact of laparoscopic staging in the treatment of pancreatic cancer Arch Surg 135 2000 409-414.
104. John TG., Wright A., Allan PL., et al. Laparoscopy with laparoscopic ultrasonography in the TNM staging of pancreatic carcinoma World J Surg 23 1999 870-881.
105. Minnard EA., Conlon KC., Hoos A., et al. Laparoscopic ultrasound enhances standard laparoscopy in the staging of pancreatic cancer Ann Surg 228 1998 182-187.
106. Makary MA., Warshaw AL., Centeno BA., et al. Implications of peritoneal cytology for pancreatic cancer management Arch Surg 133 1998 361-365.
107. Merchant NB., Conlon KC., Saigo P., et al. Positive peritoneal cytology predicts unresectability of pancreatic adenocarcinoma J Am Coll Surg 188 1999 421-426.
108. Espat NJ., Brennan MF., Conlon KC Patients with laparoscopically staged unresectable pancreatic adenocarcinoma do not require subsequent surgical biliary or gastric bypass J Am Coll Surg 188 1999 649-655.
109. Tseng JF., Raut CP., Lee JE., et al. Pancreaticoduodenectomy with vascular resection: Margin status and survival duration J Gastrointest Surg 8 2004 935-949.
110. Jimenez RE., Warshaw AL Pancreaticoduodenectomy for pancreatic cancer: Results after Kausch-Whipple and pylorus-preserving resection In: Beger H., Buchler M., Kozarek RA., et al. The pancreas: An integrated textbook of basic science, medicine and surgery 2008 Blackwell Publishing Oxford, UK.
111. ReMine WH., Priestley JT., Judd ES., et al. Total pancreatectomy Ann Surg 172 1970 595-604.
112. Brooks JR., Brooks DC., Levine JD Total pancreatectomy for ductal cell carcinoma of the pancreas. An update Ann Surg 209 1989 405-410.
113. van Heerden JA., ReMine WH., Weiland LH., et al. Total pancreatectomy for ductal adenocarcinoma of the pancreas. Mayo Clinic experience Am J Surg 142 1981 308-311.
114. Andren-Sandberg A., Ihse I Factors influencing survival after total pancreatectomy in patients with pancreatic cancer Ann Surg 198 1983 605-610.
115. Pedrazzoli S., DiCarlo V., Dionigi R., et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: A multicenter, prospective, randomized study. Lymphadenectomy study group Ann Surg 228 1998 508-517.
116. Yeo CJ., Cameron JL., Sohn TA., et al. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: Comparison of morbidity and mortality and short-term outcome Ann Surg 229 1999 613-622.
117. Yeo CJ., Cameron JL., Lillemoe KD., et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: Randomized controlled trial evaluating survival, morbidity, and mortality Ann Surg 236 2002 355-366.
118. Balcom JH., Rattner DW., Warshaw AL., et al. Ten-year experience with 733 pancreatic resections: Changing indications, older patients, and decreasing length of hospitalization Arch Surg 136 2001 391-398.
119. Buchler MW., Friess H., Wagner M., et al. Pancreatic fistula after pancreatic head resection Br J Surg 87 2000 883-889.
120. Kazanjian KK., Hines OJ., Eibl G., et al. Management of pancreatic fistulas after pancreaticoduodenectomy: Results in 437 consecutive patients Arch Surg 140 2005 849-854.
121. Mullen JT., Lee JH., Gomez HF., et al. Pancreaticoduodenectomy after placement of endobiliary metal stents J Gastrointest Surg 9 2005 1094-1104.
122. Schmidt CM., Powell ES., Yiannoutsos CT., et al. Pancreaticoduodenectomy: A 20-year experience in 516 patients Arch Surg 139 2004 718-725.
123. Sohn TA., Yeo CJ., Cameron JL., et al. Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators J Gastrointest Surg 4 2000 567-579.
124. Birkmeyer JD., Finlayson SR., Tosteson AN., et al. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy Surgery 125 1999 250-256.
125. Birkmeyer JD., Warshaw AL., Finlayson SR., et al. Relationship between hospital volume and late survival after pancreaticoduodenectomy Surgery 126 1999 178-183.
126. Bilimoria KY., Bentrem DJ., Ko CY., et al. National failure to operate on early stage pancreatic cancer Ann Surg 246 2007 173-180.
127. Geer RJ., Brennan MF Prognostic indicators for survival after resection of pancreatic adenocarcinoma Am J Surg 165 1993 68-72.
128. Benassai G., Mastrorilli M., Quarto G., et al. Survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas Chir Ital 52 2000 263-270.
129. Millikan KW., Deziel DJ., Silverstein JC., et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas Am Surg 65 1999 618-623.
130. Conlon KC., Klimstra DS., Brennan MF Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors Ann Surg 223 1996 273-279.
131. Yeo CJ., Sohn TA., Cameron JL., et al. Periampullary adenocarcinoma: Analysis of 5-year survivors Ann Surg 227 1998 821-831.
132. Kuhlmann KF., de Castro SM., Wesseling JG., et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients Eur J Cancer 40 2004 549-558.
133. Meyer W., Jurowich C., Reichel M., et al. Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas Surg Today 30 2000 582-587.
134. Shepherd HA., Royle G., Ross AP., et al. Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: A randomized trial Br J Surg 75 1988 1166-1168.
135. Smith AC., Dowsett JF., Russell RC., et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bile duct obstruction Lancet 344 1994 1655-1660.
136. Kaassis M., Boyer J., Dumas R., et al. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study Gastrointest Endosc 57 2003 178-182.
137. Soderlund C., Linder S Covered metal versus plastic stents for malignant common bile duct stenosis: A prospective, randomized, controlled trial Gastrointest Endosc 63 2006 986-995.
138. Lillemoe KD., Cameron JL., Hardacre JM., et al. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial Ann Surg 230 1999 322-328.
139. Van Heek NT., de Castro SM., van Eijck CH., et al. The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: A prospective randomized multicenter trial with special focus on assessment of quality of life Ann Surg 238 2003 894-902.
140. Graber I., Dumas R., Filoche B., et al. The efficacy and safety of duodenal stenting: A prospective multicenter study Endoscopy 39 2007 784-787.
141. Maire F., Hammel P., Ponsot P., et al. Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas Am J Gastroenterol 101 2006 735-742.
142. Lillemoe KD., Cameron JL., Kaufman HS., et al. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial Ann Surg 217 1993 447-455.
143. Polati E., Finco G., Gottin L., et al. Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer Br J Surg 85 1998 199-201.
144. Kalser MH., Ellenberg SS Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection Arch Surg 120 1985 899-903.
145. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group Cancer 59 1987 2006-2010.
146. Bakkevold KE., Arnesjo B., Dahl O., et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-Results of a controlled, prospective, randomised multicentre study Eur J Cancer 29A 1993 698-703.
147. Klinkenbijl JH., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group Ann Surg 230 1999 776-782.
148. Neoptolemos JP., Dunn JA., Stocken DD., et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial Lancet 358 2001 1576-1585.
149. Neoptolemos JP., Stocken DD., Friess H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 2004 1200-1210.
150. Small W Jr., Berlin J., Freedman GM., et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: A multicenter phase II trial J Clin Oncol 26 2008 942-947.
151. Ahlgren JD Chemotherapy for pancreatic carcinoma Cancer 78 1996 654-663.
152. Phase II studies of drug combinations in advanced pancreatic carcinoma: Fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group J Clin Oncol 4 1986 1794-1798.
153. Cullinan S., Moertel CG., Wieand HS., et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin Cancer 65 1990 2207-2212.
154. Cullinan SA., Moertel CG., Fleming TR., et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin JAMA 253 1985 2061-2067.
155. Oster MW., Gray R., Panasci L., et al. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM) Cancer 57 1986 29-33.
156. Burris HA III., Moore MJ., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial J Clin Oncol 15 1997 2403-2413.
157. Rothenberg ML., Moore MJ., Cripps MC., et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer Ann Oncol 7 1996 347-353.
158. Abou-Alfa GK., Letourneau R., Harker G., et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer J Clin Oncol 24 2006 4441-4447.
159. Berlin JD., Catalano P., Thomas JP., et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 2002 3270-3275.
160. Heinemann V., Quietzsch D., Gieseler F., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer J Clin Oncol 24 2006 3946-3952.
161. Louvet C., Labianca R., Hammel P., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 2005 3509-3516.
162. Oettle H., Richards D., Ramanathan RK., et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer Ann Oncol 16 2005 1639-1645.
163. Rocha Lima CM., Green MR., Rotche R., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 2004 3776-3783.
164. Van Cutsem E., van de Velde H., Karasek P., et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 2004 1430-1438.
165. Bramhall SR., Schulz J., Nemunaitis J., et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer Br J Cancer 87 2002 161-167.
166. Jimenez RE., Hartwig W., Antoniu BA., et al. Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: An additive strategy for cancer control Ann Surg 231 2000 644-654.
167. Moore MJ., Hamm J., Dancey J., et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 21 2003 3296-3302.
168. Bramhall SR., Rosemurgy A., Brown PD., et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial J Clin Oncol 19 2001 3447-3455.
169. Brugge WR., Lauwers GY., Sahani D., et al. Cystic neoplasms of the pancreas N Engl J Med 351 2004 1218-1226.
170. Spinelli KS., Fromwiller TE., Daniel RA., et al. Cystic pancreatic neoplasms: Observe or operate Ann Surg 239 2004 651-657.
171. Martin I., Hammond P., Scott J., et al. Cystic tumours of the pancreas Br J Surg 85 1998 1484-1486.
172. Fernandez-del Castillo C., Targarona J., Thayer SP., et al. Incidental pancreatic cysts: Clinicopathologic characteristics and comparison with symptomatic patients Arch Surg 138 2003 427-423.
173. Allen PJ., Jaques DP., D’Angelica M., et al. Cystic lesions of the pancreas: Selection criteria for operative and nonoperative management in 209 patients J Gastrointest Surg 7 2003 970-977.
174. Sperti C., Pasquali C., Chierichetti F., et al. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas Ann Surg 234 2001 675-680.
175. Compagno J., Oertel JE Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathologic study of 41 cases Am J Clin Pathol 69 1978 573-580.
176. Wilentz RE., Bores-Saavedra J., Zahurak M., et al. Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas Am J Surg Pathol 23 1999 1320-1327.
177. Tanaka M., Chari S., Adsay V., et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas Pancreatology 6 2006 17-32.
178. Crippa S., Salvia R., Warshaw AL., et al. Mucinous cystic neoplasm of the pancreas is not an aggressive entity: Lessons from 163 resected patients Ann Surg 247 2008 571-579.
179. Reddy RP., Smyrk TC., Zapiach M., et al. Pancreatic mucinous cystic neoplasm defined by ovarian stroma: Demographics, clinical features, and prevalence of cancer Clin Gastroenterol Hepatol 2 2004 1026-1031.
180. Thompson LD., Becker RC., Przygodzki RM., et al. Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: A clinicopathologic study of 130 cases Am J Surg Pathol 23 1999 1-16.
181. Zamboni G., Scarpa A., Bogina G., et al. Mucinous cystic tumors of the pancreas: Clinicopathological features, prognosis, and relationship to other mucinous cystic tumors Am J Surg Pathol 23 1999 410-422.
182. Compagno J., Oertel JE Microcystic adenomas of the pancreas (glycogen-rich cystadenomas): A clinicopathologic study of 34 cases Am J Clin Pathol 69 1978 289-298.
183. Tseng JF., Warshaw AL., Sahani DV., et al. Serous cystadenoma of the pancreas: Tumor growth rates and recommendations for treatment Ann Surg 242 2005 413-419.
184. Pyke CM., van Heerden JA., Colby TV., et al. The spectrum of serous cystadenoma of the pancreas. Clinical, pathologic, and surgical aspects Ann Surg 215 1992 132-139.
185. Albores-Saavedra J., Gould EW., Angeles-Angeles A., et al. Cystic tumors of the pancreas Pathol Ann 25 Pt 2 1990 19-50.
186. Lewandrowski K., Warshaw A., Compton C Macrocystic serous cystadenoma of the pancreas: A morphologic variant differing from microcystic adenoma Hum Pathol 23 1992 871-875.
187. Lee SE., Kwon Y., Jang JY., et al. The morphological classification of a serous cystic tumor (SCT) of the pancreas and evaluation of the preoperative diagnostic accuracy of computed tomography Ann Surg Oncol 15 2008 2089-2095.
188. Abe H., Kubota K., Mori M., et al. Serous cystadenoma of the pancreas with invasive growth: Benign or malignant? Am J Gastroenterol 93 1998 1963-1966.
189. Strobel O., Z’Graggen K., Schmitz-Winnenthal FH., et al. Risk of malignancy in serous cystic neoplasms of the pancreas Digestion 68 2003 24-33.
190. Ohashi K., Murakami Y., Maruyama M Four cases of mucin-producing cancer of the pancreas on specific findings of the papilla of Vater Prog Dig Endosc 20 1982 348-351.
191. Longnecker DS., Adler G., Hruban RH., et al. Intraductal papillary-mucinous neoplasms of the pancreas In: Hamilton SR., Aaltonen LA World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system 2000 IARC Press Lyon, France 237-240.
192. Salvia R., Fernandez-del Castillo C., Bassi C., et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: Clinical predictors of malignancy and long-term survival following resection Ann Surg 239 2004 678-685.
193. D’Angelica M., Brennan MF., Suriawinata AA., et al. Intraductal papillary mucinous neoplasms of the pancreas: An analysis of clinicopathologic features and outcome Ann Surg 239 2004 400-408.
194. Sohn TA., Yeo CJ., Cameron JL., et al. Intraductal papillary mucinous neoplasms of the pancreas: An updated experience Ann Surg 239 2004 788-797.
195. Matsumoto T., Aramaki M., Yada K., et al. Optimal management of the branch duct type intraductal papillary mucinous neoplasms of the pancreas J Clin Gastroenterol 36 2003 261-265.
196. Chari ST., Yadav D., Smyrk TC., et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas Gastroenterology 123 2002 1500-1507.
197. Papavramidis T., Papavramidis S Solid pseudopapillary tumors of the pancreas: Review of 718 patients reported in English literature J Am Coll Surg 200 2005 965-972.
198. Choi SH., Kim SM., Oh JT., et al. Solid pseudopapillary tumor of the pancreas: A multicenter study of 23 pediatric cases J Pediatr Surg 41 2006 1992-1995.
199. Kloppel G., Luttges J., Klimstra D., et al. Solid-pseudopapillary neoplasm In: Hamilton SR., Aaltonen LA World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system 2000 IARC Press Lyon, France 246-248.
200. Serra S., Salahshor S., Fagih M., et al. Nuclear expression of E-cadherin in solid pseudopapillary tumors of the pancreas J Pancreas 8 2007 296-303.
201. Chetty R., Jain D., Serra S p120 catenin reduction and cytoplasmic relocalization leads to dysregulation of E-cadherin in solid pseudopapillary tumors of the pancreas Am J Clin Pathol 130 2008 71-76.
202. Martin RC., Klimstra DS., Brennan MF., et al. Solid-pseudopapillary tumor of the pancreas: A surgical enigma? Ann Surg Oncol 9 2002 35-40.
203. Tipton SG., Smyrk TC., Sarr MG., et al. Malignant potential of solid pseudopapillary neoplasm of the pancreas Br J Surg 93 2006 733-737.
204. Mulkeen AL., Yoo PS., Cha C Less common neoplasms of the pancreas World J Gastroenterol 12 2006 3180-3185.
205. Wisnoski NC., Townsend CM Jr., Nealon WH., et al. 672 patients with acinar cell carcinoma of the pancreas: A population-based comparison to pancreatic adenocarcinoma Surgery 144 2008 141-148.
206. Koniaris LG., Lillemoe KD., Yeo CJ., et al. Is there a role for surgical resection in the treatment of early-stage pancreatic lymphoma? J Am Coll Surg 190 2000 319-330.
207. Saif MW Primary pancreatic lymphomas JOP 7 2006 262-273.